Boehringer Will Get Study Info in Humira Fight With AbbVie

摘要

Boehringer Ingelheim International GmbH can obtain Humira clinical study data from researchers in its patent fight with AbbVie Inc. over the blockbuster drug. Humira seller AbbVie had sought to block Boehringer from obtaining the data, arguing that patient records would be disclosed, responding to subpoenas would be too taxing on the researchers, and the company could provide the information on its own anyway. A federal magistrate judge rejected those arguments May 23 in an AbbVie patent infringement suit seeking to stop a bio-similar version of Humira from entering the market Humira, a biologic, is the world's best-selling drug, and protecting it from competition is a priority for AbbVie. The product generated $18.4 billion in worldwide sales for AbbVie in 2017, which was 65.2 percent of the company's total net revenues, according to its latest annual report. Humira sales reached $16.1 billion in 2016 and $14 billion in 2015.